Research Article
Laboratory Indicators of Aggrecan Turnover in Juvenile Idiopathic Arthritis
Table 1
Clinical characteristics of control subjects and JIA disease patients.
| | Parameter | Control subjects
() | Untreated JIA
() | JIA disease after attainment of clinical improvement
() |
| | Age (years) | 8.67 ± 4.12 | 7.27 ± 4.49 | 8.21 ± 4.01 | | Sex, female/male | 17/13 | 19/11 | 19/11 | | JADAS-27 | — | 18 ± 8.56 | 4 ± 2.52 | | WBC (103/μL) | 7.32 ± 2.19 | 10.04 ± 4.03 | 7.14 ± 2.31 | | RBC (106/μL) | 4.95 ± 0.35 | 4.48 ± 0.41 | 4.62 ± 0.36 | | Hb (g/dL) | 13.85 ± 0.94 | 11.58 ± 1.38 | 12.97 ± 1.16 | | Ht (%) | 40.96 ± 3.18 | 35.35 ± 3.61 | 37.17 ± 7.39 | | PLT (103/μL) | 283.47 ± 73.83 | 405.47 ± 129.10 | 351.20 ± 93.78 | | Total cholesterol (mM) | 4.12 ± 0.87 | 4.61 ± 1.42 | 4.25 ± 1.65 | | Glucose (mM) | 4.56 ± 0.38 | 4.11 ± 1.16 | 4.40 ± 0.98 | | Creatinine (μM) | 80.01 ± 12.66 | 52.97 ± 10.23 | 64.54 ± 15.47 | | CRP (mg/L) | 1.24 ± 1.59 | 20.25 ± 24.00 | 2.76 ± 0.57 | | ESR (mm/h) | 10.50 ± 7.03 | 42.00 ± 27.02 | 13.11 ± 7.21 | | ANA | — | 56% (positive) | 56% (positive) | | RF | — | 100% (negative) | 100% (negative) | | MMP-3 (ng/mL) | 0.26 ± 0.13 | 2.25 ± 1.36 | 0.55 ± 0.25 | | #ADAMTS-4 (ng/mL) | 15.55 ± 6.70 | 26.71 ± 15.17 | 13.26 ± 8.10 | | #TGF-β (ng/mL) | 5.70 ± 1.93 | 8.13 ± 3.24 | 3.88 ± 1.82 | | #PDGF-BB (ng/mL) | 1.19 ± 0.54 | 1.64 ± 0.75 | 0.85 ± 0.49 |
|
|
Results are expressed as mean ± SD; compared to control group; compared to untreated JIA patients; WBC, white blood cell; RBC, red blood cell; Hb, hemoglobin; Ht, hematocrit; PLT, platelet; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ANA, antinuclear antibodies; RF, rheumatoid factor; MMP, matrix metalloproteinase; ADAMTS, a disintegrin and metalloprotease with thrombospondin motifs; TGF-β, transforming growth factor-beta; PDGF-BB, platelet derived growth factor-BB; results reported in [7]; #results reported in [9].
|
